This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This clause establishes the conditions under which 23andMe may utilize genetic data for research, product development, and other purposes without individual consent requirements. The authorization to use de-identified and aggregated data without restriction creates a distinct operational pathway from identifiable data use.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth is governed by different privacy rules. Previously, the policy stated that users choosing telehealth services coordinated through 23andMe would find healthcare privacy protections described in a separate notice. That reference is now absent from the main privacy statement. Users seeking privacy information specific to telehealth services will need to determine independently whether a separate notice exists or contact 23andMe directly using the provided contact information.
View change record →The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for telehealth services. Users who receive telehealth services coordinated through 23andMe may now lack clear notice of which privacy framework governs their medical records, since the reference to that parallel notice has been removed. The organizational scope change from '23andMe Research Institute' to '23andMe' narrows the explicitly named entities responsible for the policy, though operational impact depends on how these entities actually function.
View change record →Users' genetic and self-reported information may be processed into de-identified or aggregated datasets that 23andMe can use without additional restrictions or notification. The terms authorize this use of processed data as part of the service operation.
How other platforms handle this
We may share your personal information with our affiliates, meaning entities that control, are controlled by, or are under common control with Consensys. We also share information with service providers who assist in operating our services, subject to confidentiality obligations.
At Ledger, earning and maintaining our users' trust is a top priority. That's why we are deeply committed not only to protecting your privacy and securing your personal data, but also to being fully transparent about how we handle it.
RedCard. We share information with our financial partners to operate the Target RedCard program.
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 25 platforms.
"23andMe may use your Genetic Information and/or Self-Reported Information in a de-identified or aggregated form. De-identified data is data that has had all identifying information removed or altered so that a reasonable person would not be able to identify you from this data. Aggregated data is a collection of individual data that has been combined so that individual results are not visible. We may use de-identified or aggregated information without restriction.— Excerpt from 23andMe's 23andMe Privacy Statement
ConductAtlas detected a major restructuring of Meta’s privacy policy that removed detailed consumer rights disclosures and relocated them to separate documents.
Your genetic data may be transferred to a new owner as a business asset. Here is what the Terms of Service actually say and what you can do right now.
Compliance Governance Intelligence
Need to monitor specific governance provisions?
Compliance includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
This clause establishes the conditions under which 23andMe may utilize genetic data for research, product development, and other purposes without individual consent requirements. The authorization to use de-identified and aggregated data without restriction creates a distinct operational pathway from identifiable data use.
Users' genetic and self-reported information may be processed into de-identified or aggregated datasets that 23andMe can use without additional restrictions or notification. The terms authorize this use of processed data as part of the service operation.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.